ClinicalTrials.gg
CompletedNCT03457649Updated May 23, 2024

IV Dose Study to Assess the Safety, Tolerability, PK, PD and Immunogenicity of ARGX-113 in Healthy Volunteers

A Phase 1 interventional study of ARGX-113 and Placebo in Healthy Volunteers, sponsored by argenx. Completed. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-05-23.

Sponsored by argenx · Phase 1, Interventional, and Other

From the registry’s dates

  • Registered 2 years 5 months after the study started (first participant enrolled Sep 2015, registered Feb 2018).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
62
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

A phase 1 study in healthy volunteers (female and male) to evaluate through SAD and MAD, the safety, PK, PD and immunogenicity of ARGX-113 administered intravenously.

Read the detailed description

The phase 1 in healthy volunteers include:

SAD with 5 doses of test product and placebo

MAD with 2 doses and two dosing intervals of the test product and placebo

The safety, pharmacokinetics, pharmacodynamics and immunogenicity of the test product are evaluated.

02

Conditions studied

  • Healthy Volunteers
03

In context

Lead sponsor

argenx is the lead sponsor of 87 studies on the registry; 28 are open to participants now.

Of its 22 completed or terminated interventional studies of FDA-regulated products, 16 (73%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Subjects meeting all of the following criteria are eligible to participate in this study:

  1. Willingness and ability to understand the purpose and risks of the study and provide signed and dated prior to any procedures and be available for all study visits.
  2. Male or female of non-child bearing potential, between 18-55 years of age, inclusive, on the day of signing the Informed Consent Form (ICF).
  3. (BMI) between 18-30 kg/m2, inclusive with a weight of at least 50 kg and no more than 100 kg.
  4. Female subjects must have a negative blood pregnancy test at screening and a negative urine pregnancy test at Day -1.
  5. Female subjects who are or surgically sterile (having had a hysterectomy, bilateral oophorectomy, or tubal ligation). Determination of serum follicle-stimulating hormone (FSH) will be done with FSH levels > 35 mIU/mL being confirmative for menopause. For hysterectomy and tubal ligation, documented confirmation will be requested.
  6. Non-vasectomized male subjects having a female partner of must agree to the use of an effective method of until 90 days after the last administration of study drug.
  7. Male subjects have to agree not to donate sperm until 90 days after the last administration of study drug.
  8. Judged by the investigator to be in good health based upon the results of a medical history, physical examination, vital signs, 12-lead (ECG), and laboratory findings.
  9. Discontinuation of all medications (including over-the-counter and/or prescription medication, dietary supplements, neutraceuticals, vitamins and/or herbal supplements such as Ginkgo biloba or Saint John's wort), except occasional paracetamol use (maximum dose of 2 g/day and maximum of 10 g/2 weeks), at least 2 weeks prior to the first study drug administration. In addition, subjects must agree to the prohibitions and restrictions for this study.
  10. Non-smokers, and not using any nicotine-containing products. A non-smoker is defined as an individual who has abstained from smoking for at least 1 year prior to the screening.
  11. Negative urine drug screen (amphetamines, barbiturates, benzodiazepines, cannabis, cocaine, opiates, methadone, and tricyclic antidepressants) at screening and Day -1.
  12. Negative alcohol breath test at screening and Day-1. Note: A retest can be done in case of an out of range clinical laboratory test value that will determine a subject's eligibility. This retest should preferably be done at an unscheduled visit. The result of the retest will be considered for subject eligibility. If the retest is outside normal reference ranges, the subject may be included only if the investigator judges the abnormalities to be not .

Exclusion criteria

Exclusion Criteria:

Subjects meeting any of the following criteria are excluded from participation in this study:

  1. Known to study drug ingredients or a significant allergic reaction to any drug as determined by the investigator, such as anaphylaxis requiring hospitalization.
  2. Positive serology for virus surface antigen (HBsAg) or virus (HCV) or any history of hepatitis from any cause with the exception of hepatitis A.
  3. History of or a current condition (e.g., [HIV] infection).
  4. History of or evidence of active or latent or inadequately treated infection with Mycobacterium tuberculosis (TB) diagnosed by a positive QuantiFERON® TB-Gold In Tube test or a positive tuberculin skin test ("Mantoux") in case of a weak positive QuantiFERON® TB-Gold In Tube test.
  5. Subjects with known immunological disorders.
  6. History of severe allergic or anaphylactic reactions.
  7. Symptoms of clinically significant illness in the 3 months before the initial study drug administration.
  8. Presence or having sequelae of gastrointestinal, liver, kidney or other conditions known to interfere with the absorption, distribution, metabolism, or excretion of drugs.
  9. History of within the past 5 years (except for basal cell carcinoma of the skin that has been treated with no evidence of recurrence).
  10. Clinically relevant abnormalities detected on regarding either rhythm or conduction (e.g., > 450 ms [male subjects] or >470 [female subjects], or a known long QT syndrome). A first degree heart block or sinus arrhythmia will not be considered as a significant abnormality.
  11. Clinically relevant abnormalities detected on vital signs
  12. Significant blood loss (including blood donation [> 500 mL]), or had a transfusion of any blood product within 12 weeks prior to the initial study drug administration or plan one within 4 weeks after the end of the study.
  13. Treatment with any drug known to have a well-defined potential for toxicity to a major organ in the last 3 months preceding the initial study drug administration.
  14. The subject has a history of consuming more than 21 (14 for females) units of alcoholic beverages per week or has a history of alcoholism or drug/chemical/substance abuse within past 2 years prior to screening (Note: one unit = 330 mL of beer, 110 mL of wine or 28 mL of spirits). Consumption of a large quantity of coffee, tea (> 6 cups per day) or equivalent.
  15. Administration of an injectable drug within 30 days prior to the initial study drug administration.
  16. Concurrent participation, or participation within 8 weeks prior to the initial study drug administration in a drug/device or biologic research study, or participation within 15 weeks prior to initial study drug administration in an investigational research study with biologic response modifier administration.
  17. Administration of a vaccine within 60 days prior to initial study drug administration.
  18. Administration of any systemic immunosuppressant agent within 6 months prior to initial study drug administration.
  19. Administration of any systemic within 2 months prior to initial study drug administration;
  20. Use of a prohibited therapy within 14 days prior to initial study drug administration.
  21. Investigator or any sub-investigator, research assistant, pharmacist, study coordinator, or other staff or relative thereof who is directly involved in the conduct of the study.
  22. Any condition or circumstances that in the opinion of the investigator may make a subject unlikely or unable to complete the study or comply with study procedures and requirements.
  23. Pregnant or lactating women or women of .
  24. Unsuitable vein for infusion and/or blood sampling.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
62 participants (actual)

Study arms

  • Active comparator
    ARGX-113

    SAD and MAD with test product at different increasing doses

    Biological: ARGX-113

  • Placebo comparator
    Placebo

    SAD and MAD with placebo at different increasing doses

    Biological: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Number of (related) treatment emergent AE of single ascending dose of ARGX-113

    Determining the incidence, severity, and dose relationship of adverse events that are related to treatment with ARGX-113

    Time frame: 57 days

Secondary outcomes

  1. Number of (related) treatment emergent AE of multiple ascending doses of ARGX-113

    Determining the incidence, severity, and dose relationship of adverse events that are related to treatment with ARGX-113

    Time frame: 78 days

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Ulrichts P, Guglietta A, Dreier T, van Bragt T, Hanssens V, Hofman E, Vankerckhoven B, Verheesen P, Ongenae N, Lykhopiy V, Enriquez FJ, Cho J, Ober RJ, Ward ES, de Haard H, Leupin N. Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans. J Clin Invest. 2018 Oct 1;128(10):4372-4386. doi: 10.1172/JCI97911. Epub 2018 Jul 24. PubMed 30040076 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2015 to primary completion in Nov 2016, 14 months.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 9, 2018
First posted
Mar 7, 2018
StartActual
Sep 9, 2015
Primary completionActual
Nov 15, 2016
CompletionActual
Feb 21, 2017
Last update
May 23, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 23, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03457649
Lead sponsor
argenx
Responsible party
Sponsor
First posted
Mar 7, 2018
Start date
Sep 9, 2015
Primary completion
Nov 15, 2016
Completion
Feb 21, 2017
Last update
May 23, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Efgartigimod alfa

Start the discussion